TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25399973
Drug: Paclitaxel/Carboplatin (Carboplatin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/Carboplatin (Carboplatin: AUC 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; Paclitaxel: 200 mg/m², 21-day cycle)
Study: 10576189
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 50 microg every 4 hours as needed
Study: 1662638
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1, 250 mg on days 2-5)
Study: 1662638
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg b.i.d. for ten days)
Study: 7046908
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg/m2 orally three times a week) with chemotherapy
Study: 7046908
Drug: Reduced dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced dosage of levamisole (2.5 mg/kg or 100 mg/m2 three times a week, every other week) with chemotherapy
Study: 21845387
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of dexamethasone (8 mg)
Study: 21845387
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of dexamethasone (8 mg)
Study: 16167288
Drug: Fixed-combination brimonidine
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID (n = 188)
Study: 16167288
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (fixed-combination and concomitant)
Study: 8679790
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg TRH just prior to ECT
Study: 2066545
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at bedtime and Placebo
Study: 6606576
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (aorto-coronary bypass surgery)
Study: 26280534
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (60 mg)
Study: 17523910
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg/day for 4 weeks (group C)
Study: 17523910
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg/day for 4 weeks (group D)
Study: 6342353
Drug: Prazosin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 20 mg/day
Study: 31755292
Drug: collagen 4
Normalized name: collagen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: collagen 4 ml
Study: 31755292
Drug: trimecaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimecaine 1% 4 ml
Study: 25457123
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment (PST) - six 1-hour sessions
Study: 23284689
Drug: SRT2104 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (0.5 or 2.0 g)
Study: 15707388
Drug: CC carriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC carriers
Study: 12072722
Drug: Desonide 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desonide 0.25% ophthalmic solution
Study: 9491286
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of intravenous iron dextran for 6 weeks
Study: 27222511
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol levels >2.5 mmol/L
Study: 14632771
Drug: Intermediate-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cytosine arabinoside (1 g/m2/2 h) b.i.d. for 4 days with idarubicin (CCI)
Study: 1679065
Drug: Oxatomide 1
Normalized name: chlophedianol hydrochloride 15 MG / guaiacol ethylglycolate 10 MG / oxatomide 10 MG per 5 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide 1 mg/kg/day
Study: 24831445
Drug: VAS203 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAS203 (20 mg/kg for 48 hours)
Study: 24831445
Drug: VAS203 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAS203 (30 mg/kg for 72 hours)
Study: 8151105
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months plus 150 mg of levamisole for the first 6 weeks
Study: 3731535
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol content beer (64 ml/week)
Study: 3731535
Drug: Normal drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal drinking habits (452 ml ethanol/week)
Study: 23164997
Drug: PGA sheet
Normalized name: PGA
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGA sheet and fibrin glue spray
Study: 21252701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Telmisartan 80 mg and Nifedipine GITS 20 mg
Study: 7515730
Drug: CEMB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMB regimen (cisplatin 50 mg/m2 day 1, vindesin 3 mg/m2 day 1, mitomycin 6 mg/m2 day 2, bleomycin 15 mg/day, day 1 + 2 by continuous infusion)
Study: 31082494
Drug: Afatinib in
Normalized name: Product containing afatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib in combination with postoperative radiation therapy (PORT)
Study: 31082494
Drug: Afatinib in
Normalized name: Product containing afatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib in combination with PORT and weekly docetaxel
Study: 31082494
Drug: Afatinib in
Normalized name: Product containing afatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib in combination with PORT
Study: 30650497
Drug: Modified Dachengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Dachengqi Decoction (500 mL) once a day for 2 weeks
Study: 9795924
Drug: CIFN 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN 9 micrograms, three times weekly for 24 weeks
Study: 9795924
Drug: CIFN 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN 15 micrograms, three times weekly for 48 weeks
Study: 9795924
Drug: IFN‐alpha‐2b 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2b 3 MU administered 3 times per week for 6 to 12 months
Study: 22030199
Drug: Lidocaine jet
Normalized name: lidocaine Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine jet injection (0.2 mL of lidocaine 2%)
Study: 19606510
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list, no treatment)
Study: 9504953
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified liquid milk (500 ml per day)
Study: 1673134
Drug: Metoprolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 100 mg twice daily
Study: 30899086
Drug: Molecular apocrine
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular apocrine (MA) subtype patients receiving neoadjuvant chemotherapy
Study: 19848196
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI), 60 mL once a day for 10 days each month over a treatment course of 6 months.
Study: 19848196
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (Control group).
Study: 3704898
Drug: Subcutaneous drains
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drains
Study: 11968069
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release formulations of metoprolol (100 mg) with varying release rates (slow, moderate, fast)
Study: 11968069
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of metoprolol (50 mg)
Study: 11968069
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release formulations of metoprolol (100 mg) with fast input
Study: 10886120
Drug: GR205171 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR205171 25 mg i.v.
Study: 28297698
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 3 months)
Study: 20156926
Drug: TPA023B (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA023B (1.5 mg)
Study: 20156926
Drug: TPA023B (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA023B (10 mg/kg)
Study: 30595329
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg/day
Study: 29415258
Drug: Brexpiprazole 1-4
Normalized name: brexpiprazole 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 1-4 mg/d
Study: 27530473
Drug: Anthocyanin-rich purple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin-rich purple sweet potato beverage (PSP), 177 mg anthocyanins per 125-ml bottle, 3 bottles per day for 8 weeks
Study: 25069476
Drug: Genetic variants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic variants associated with drug reactions (rs1799929 and rs1495741 in NAT2)
Study: 327854
Drug: Droperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (5 mg)
Study: 31501069
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution)
Study: 21917777
Drug: Responsive cortical
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responsive cortical stimulation (treatment)
Study: 11378006
Drug: Metoprolol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50, 100, and 200 mg)
Study: 11378006
Drug: Carvedilol (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25, 50, and 100 mg)
Study: 7954233
Drug: Temporary hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary hepatic artery occlusion followed by intraportal infusion of 5‐fluorouracil (5‐FU) and oral allopurinol
Study: 7954233
Drug: No regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regional or systemic treatment
Study: 31724966
Drug: placebo 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1.5 ml, pen-injector for subcutaneous injection
Study: 18679148
Drug: Noninvasive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ventilation (NIV) plus standard therapy
Study: 15381054
Drug: Aggrenox (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggrenox (2 pills/daily)
Study: 15381054
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg plus matching placebo/daily)
Study: 11183453
Drug: Clindamycin ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin ovule (3-day treatment)
Study: 30367673
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal gel
Study: 8752295
Drug: Bovine rotavirus
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine rotavirus vaccines
Study: 8752295
Drug: RRV-based vaccines
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-based vaccines
Study: 8752295
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines with demonstrable immunogenicity
Study: 1371211
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus intravenous cyclophosphamide
Study: 29908826
Drug: Intramyocardial CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial CD34+ cell therapy (5 × 10^4 to 5 × 10^5 cells/kg)
Study: 15200199
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (4mg)
Study: 9916605
Drug: Valsartan 10
Normalized name: valsartan 103 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 10 mg
Study: 9220209
Drug: Valsartan 20
Normalized name: valsartan 20 MG in 5 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 20 mg
Study: 20236700
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg
Study: 3195836
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (20 mg 3 times a day)
Study: 9004191
Drug: Extended-release experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release experimental formulations (80 mg)
Study: 9004191
Drug: Inderal immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal immediate-release dosage form (2 x 40 mg)
Study: 1359318
Drug: Mefloquine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 1250 mg in divided doses
Study: 18230968
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Study: 2129319
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg PM
Study: 2129319
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg bid
Study: 2129319
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg AM
Study: 19242406
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg memantine
Study: 8628597
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/d
Study: 29650688
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy (doxorubicin, doxorubicin + ifosfamide, epirubicin, trabectedin, ifosfamide)
Study: 24852464
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream applied every day for 4 weeks
Study: 24852464
Drug: 4 weekly
Normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly peels of 5% 5-fluorouracil
Study: 22573238
Drug: Increases in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increases in ESA doses (>0 U)
Study: 22573238
Drug: Larger increases
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger increases in hemoglobin (>1.0 g/dL/month)
Study: 15178637
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 4 weeks
Study: 10097818
Drug: Short peptides
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short peptides with Tpo activity; details on dosage and duration not available.
Study: 3512670
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg
Study: 701072
Drug: Lioresal (antispasticity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lioresal (antispasticity drug)
Study: 31511041
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and liberal intraoperative blood glucose management
Study: 11295008
Drug: Hospital outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital outpatient clinic injections by medical staff
Study: 11295008
Drug: Home injections
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home injections by the nurse practitioner
Study: 9047153
Drug: sTNFR:Fc therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTNFR:Fc therapy
Study: 8451040
Drug: Oral medium-dosed
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medium-dosed metoclopramide (MCL, 3.5 mg/kg b.w./cycle)
Study: 3530049
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, 1.5 mg/kg, administered 2 minutes before laryngoscopy and intubation
Study: 18308741
Drug: Terlipressin 1
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 1 mg
Study: 18308741
Drug: Terlipressin 1
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 1 mg followed by dobutamine infusion titrated to reverse the anticipated reduction in Svo2
Study: 1508058
Drug: Oestriol (E3)
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol (E3) 0.5 mg administered intravaginally daily for 2 weeks, then once or twice weekly for 4 weeks as maintenance dose.
Study: 24118972
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily PTNS
Study: 24118972
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly PTNS
Study: 15204160
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream plus PUVA therapy
Study: 11264634
Drug: Nystatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (5 mL oral suspension, four times daily)
Study: 11264634
Drug: Clotrimazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (10 mg troche, three times daily)
Study: 26673560
Drug: Polypharmacy (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (≥ 10 medications)
Study: 18664560
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg/day for 2 years
Study: 12719503
Drug: Nurse-administered Structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered Structured Clinical Interview for DSM-IV-Clinician Version (SCID)
Study: 7490838
Drug: 8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of reversible androgen ablation therapy
Study: 1586932
Drug: Enalapril (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (3 months therapy)
Study: 20410252
Drug: Additional psychological
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional psychological treatment (written information on medical and psychological consequences of an ICD plus 6 months of individual phone counseling)
Study: 20410252
Drug: Additional psychological
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional psychological treatment
Study: 18509656
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 100 mL of 300 mg I/mL at 5.0 mL/s
Study: 18509656
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 100 mL of 300 mg I/mL at 3.5 mL/s
Study: 18509656
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 100 mL of 350 mg I/mL at 3.5 mL/s
Study: 12204703
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost once daily (n = 737)
Study: 12204703
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol twice daily (n = 652)
Study: 8739541
Drug: Pentoxifylline 600
Normalized name: pentoxifylline 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 600 mg intravenously twice a day
Study: 10482146
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus cilostazol
Study: 17949573
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment by family doctors unaware of the guideline
Study: 17949573
Drug: Clinical practice
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical practice guideline treatment
Study: 23388530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment
Study: 11866684
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (control group)
Study: 22357255
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg b.i.d.
Study: 20353107
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Sparfloxacin tablets and Prostat tablets); oral administration
Study: 15841494
Drug: Mobicox (meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobicox (meloxicam 7.5 mg)
Study: 3266333
Drug: Bromocriptine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine therapy
Study: 359925
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of Rifampicin daily for 3 months
Study: 30919998
Drug: EA-230 (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (15, 45 and 90 mg/kg/h)
Study: 24190844
Drug: Individual adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual adolescent focused therapy (AFT)
Study: 8431119
Drug: Cimetidine continuous
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine continuous infusion
Study: 3582476
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 and 650 mg)
Study: 6088252
Drug: Triprolidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (10 mg)